Hecogenin acetate

Synonyms: 龙舌兰皂苷乙酯
Hecogenin acetate 是一种口服有效的甾体皂苷元,具有广泛的生物活性:它通过抑制 NF-κB 和 p38 MAPK 信号通路的磷酸化、拮抗 TRPA1/TRPM8 通道以及抑制促炎细胞因子的产生而发挥消炎镇痛作用,同时抑制 ROS 产生和 NLRP3 炎症小体激活、下调 MMP-2 表达,从而具有神经保护和抗肿瘤活性,还能抑制醛固酮合酶基因表达并增加尿量和电解质排泄,此外可与某些抗生素联用,通过调节细菌外排泵恢复抗生素敏感性。
产品编号: MS-F26765 纯度: 98.57% CAS No.: 915-35-5 分子式: C29H44O5 分子量: 472.66
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Hecogenin acetate 是一种口服有效的甾体皂苷元,具有广泛的生物活性:它通过抑制 NF-κB 和 p38 MAPK 信号通路的磷酸化、拮抗 TRPA1/TRPM8 通道以及抑制促炎细胞因子的产生而发挥消炎镇痛作用,同时抑制 ROS 产生和 NLRP3 炎症小体激活、下调 MMP-2 表达,从而具有神经保护和抗肿瘤活性,还能抑制醛固酮合酶基因表达并增加尿量和电解质排泄,此外可与某些抗生素联用,通过调节细菌外排泵恢复抗生素敏感性。

生物实验数据

生物活性 Hecogenin acetate is an orally effective steroidal sapogenin with a broad spectrum of biological activities: it exerts anti-inflammatory and analgesic effects by inhibiting the phosphorylation of the NF-κB and p38 MAPK signaling pathways, antagonizing TRPA1/TRPM8 channels, and suppressing pro-inflammatory cytokine production, while also inhibiting ROS production and NLRP3 inflammasome activation and downregulating MMP-2 expression, thereby exhibiting neuroprotective and antitumor activities; furthermore, it inhibits aldosterone synthase gene expression and increases urine output and electrolyte excretion, and can be used in combination with certain antibiotics to restore antibiotic sensitivity by modulating bacterial efflux pumps.
IC50 & Target

p38 MAPK

 

NF-κB

 

ERK1

 

ERK2

 

MMP-2

 

NLRP3 inflammasome

 

IL-1β

 

IL-6

 

体外研究
(In Vitro)

Hecogenin acetate 仅有很弱的直接抗菌活性,对 S. aureus ATCC 和 E. coli ATCC 的 MIC 分别为 645 μg/mL 和 512 μg/mL。
Hecogenin acetate (1-150 μM, 24 h) 在浓度低于 75 μM 时对 A549 细胞活力无显著影响,高浓度时降低 A549 细胞的活力。
Hecogenin acetate (50 μM, 24 h) 在 A549 细胞中逆转由 H₂O₂ 引起的细胞膜损伤、ROS 产生和过氧化氢酶 (CAT) 和超氧化物歧化酶 (SOD) 活性升高。
Hecogenin acetate (25-100 μM, 24-72 h) 通过抑制 ERK1/2 信号通路和降低 MMP-2 的表达,诱导 G0/G1 期细胞周期阻滞和细胞衰老。

Cell Cycle Analysis

Cell Line: A549 cells
Concentration: 25, 50, 75 and 100 μM
Incubation Time: 72 h
Result: Dose-dependently arrested A549 cells in the G0/G1 phase.

Western Blot Analysis

Cell Line: A549 cells
Concentration: 50 μM
Incubation Time: 24 h
Result: Completely blocked the ERK1/2 phosphorylation induced by H₂O₂.
Inhibited the upregulation of matrix metalloproteinase-2 (MMP-2) expression caused by H₂O₂.
体内研究
(In Vivo)

Hecogenin acetate (20 mg/kg,灌胃,每日一次,持续 8 或 15 天) 可显著缓解小鼠的慢性炎症性疼痛和神经性疼痛。
Hecogenin acetate (5-25 mg/kg,腹腔注射,单次给药或每日一次,持续 7 天) 可抑制醛固酮合成酶 (CYP11B2) 基因的表达,从而在大鼠中发挥利尿作用。
Hecogenin acetate (2.5-10 mg/kg,口服,单次给药或每日一次,持续 7 天) 在啮齿类动物模型中对各种化学物质 (无水乙醇、酸化乙醇) 和病理过程 (缺血再灌注) 引起的急性胃黏膜损伤具有显著的保护作用。

Animal Model: Gastric injury induced by ischemia-reperfusion established in 2-month male Swiss mice weighing between 25 and 30 g
Dosage: 20 mg/kg
Administration: Intragastric administration (i.g.), once daily for 8 days (chronic pain model) or 15 days (neuropathic pain model model)
Result: Exhibited potent and long-lasting anti-allodynic effects in both chronic and neuropathic pain models.
Inhibited the activation of spinal microglia, reduce the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and inhibit the activation of the NF-κB and p38 MAPK signaling pathways.
Antagonized TRPM8 and TRPA1 ion channels, reducing the sensitization of peripheral nociceptive receptors.
Animal Model: Acute and subacute diuretic assays established in Sprague-Dawley rats (180-240 g)
Dosage: 5, 10 and 25 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose or once daily for 7 days
Result: Had a dose-dependent diuretic effect, which can significantly increase urine output and the excretion of sodium and chloride ions.
Showed the characteristics of sodium and chlorine excretion while maintaining relatively high potassium levels.
Down-regulated the expression of the aldosterone synthase (CYP11B2) gene in the adrenal gland to inhibit aldosterone synthesis.
Animal Model: Acute gastric ulcers induced by anhydrous ethanol and acidified ethanol established in 2-month male Swiss mice eighing between 25 and 30 g
Dosage: 5, 10, 20 mg/kg
Administration: Oral administration (p.o.), single dose
Result: Had a strong protective effect against acute gastric mucosal injury caused by anhydrous ethanol.
Effectively resisted more severe damage to the gastric mucosa caused by the combined attack of ethanol and gastric acid.
Animal Model: Gastric injury induced by ischemia-reperfusion and chronic gastric ulcers induced by acetic acid established in male Sprague-Dawley rats (250-300 g)
Dosage: 5, 10, 20 mg/kg
Administration: Oral administration (p.o.), single dose (gastric injury model) or once daily for 7 days (chronic gastric ulcers mmodel)
Result: Had a strong protective effect against ischemia-reperfusion gastric injury mediated by oxidative stress.
Effectively promoted the healing of chronic gastric ulcers.
性状 固体
颜色 White to yellow

化学信息

分子量 472.66
分子式 C29H44O5
CAS No. 915-35-5
别名 龙舌兰皂苷乙酯

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

THF 中的溶解度 : 57.5 mg/mL (121.65 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
THF1 mM2.1157 mL10.5784 mL21.1569 mL52.8921 mL
5 mM0.4231 mL2.1157 mL4.2314 mL10.5784 mL
10 mM0.2116 mL1.0578 mL2.1157 mL5.2892 mL
15 mM0.1410 mL0.7052 mL1.4105 mL3.5261 mL
20 mM0.1058 mL0.5289 mL1.0578 mL2.6446 mL
25 mM0.0846 mL0.4231 mL0.8463 mL2.1157 mL
30 mM0.0705 mL0.3526 mL0.7052 mL1.7631 mL
40 mM0.0529 mL0.2645 mL0.5289 mL1.3223 mL
50 mM0.0423 mL0.2116 mL0.4231 mL1.0578 mL
60 mM0.0353 mL0.1763 mL0.3526 mL0.8815 mL
80 mM0.0264 mL0.1322 mL0.2645 mL0.6612 mL
100 mM0.0212 mL0.1058 mL0.2116 mL0.5289 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

龙舌兰皂苷乙酯 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础